3 Dr. Reddy’s Inspection Observations
FDA has released the FDA-483 issued following a 9/11-9/15 inspection at the Dr. Reddy’s drug manufacturing facility in Mirfield, West Yorkshire, UK. The specific observations cited were:
- procedures are not established or followed;
- cleaning procedures or clean status is not established; and
- manually managed materials in the warehouse are not separated during storage.